Glaukos Announces First Quarter 2023 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highl...

Related Keywords

Thomas Burns ,Chris Lewis ,International Glaucoma ,Investor Relations Corporate Affairs ,Avedro Inc ,Ivantis Inc ,Exchange Commission ,Corneal Health ,Glaukos Corporation ,Investor Relations ,Quarterly Summary ,Micro Invasive Glaucoma Surgery ,Annual Report ,Quarterly Report ,Investor Section ,Regarding Use ,Generally Accepted Accounting Principles ,Corporate Affairs ,